Enliven Therapeutics has reported encouraging early results from a Phase 1 clinical trial of ELVN-001, a novel small molecule kinase inhibitor targeting chronic myeloid leukemia (CML).

Lamassu Biotech has received approval from the FDA to commence Phase 1/2a clinical trials for its innovative cancer treatment, SA53-OS.

MEI Pharma's Board of Directors has made a strategic decision to focus on the clinical development of their drug candidates, voruciclib and ME-344, based on positive clinical data.

April 12, 2024 —Cbio A/S, a biopharmaceutical firm based in Copenhagen, has announced its financial results for 2023 and provided an update on the company's progress.

Agenus Inc. has reported new findings from its Phase 1 clinical study of BOT/BAL combination therapy for patients with metastatic colorectal cancer (CRC).

In a recent analysis of 7,200 cancer research abstracts from the American Association for Cancer Research's (AACR) annual gathering, several significant trends emerged.

April 15, 2024 —An innovative gene therapy named AVB-101 is currently under investigation to treat frontotemporal dementia (FTD) caused by progranulin (GRN) gene mutations.

April 15, 2024 —NiKang Therapeutics Inc. recently announced the commencement of a phase 1/1b clinical trial involving their novel drug candidate NKT3447.

April 15, 2024 —Neumora Therapeutics, a biopharmaceutical firm listed on Nasdaq as NMRA, has encountered a setback in its clinical trials.

April 15, 2024 —Walden Biosciences, a private clinical development company, has reported positive results from its Phase 1+ study of WAL0921.

April 15, 2024 —A recent publication in Nature Medicine has highlighted the advancements in vaccine design, specifically focusing on Gritstone bio's neoantigen platform, SLATE.

April 15, 2024 —In a recent study, patients with Angelman syndrome demonstrated significant improvements in various areas after treatment with GTX-102.